Which is better, ipamorelin or GHRP-6?
Both are graded human RCT, and in neither case does the randomized evidence cover the uses they are sold for. Ipamorelin's one randomized, placebo controlled trial tested intravenous dosing after bowel surgery and found no benefit. GHRP-6's randomized studies measured hormone and sleep responses, and its one phase III trial gave it only in combination with epidermal growth factor for stroke and missed its primary endpoint. Ipamorelin showed better hormonal selectivity than GHRP-6 in the direct animal comparison. Regulatory status offers no tiebreak: GHRP-6 is in 503B Category 2, ipamorelin went through 503A Category 2 to a withdrawn nomination and ipamorelin acetate remains in 503B Category 2, and neither has a lawful compounding path. No human trial has compared them. [1] [2] [6] [9] [10] [12] [13]
How do ipamorelin and GHRP-6 compare?
| Dimension | Ipamorelin | GHRP-6 |
|---|---|---|
| Structure [1] [5] | Pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), derived from the GHRP series. | Hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2), the original GHRP described in 1984. |
| Direct animal comparison [1] | In conscious pigs, GH release with potency and efficacy similar to GHRP-6 (ED50 about 2.3 nmol/kg), with no rise in ACTH or cortisol even at 200 times the GH ED50. | Similar GH release but also raised ACTH and cortisol in the same study. |
| Human evidence [2] [6] [7] [12] [13] | One randomized trial (117 adults after bowel resection, intravenous): no significant effect on time to first tolerated meal (25.3 versus 32.6 hours, p = 0.15). A separate study in 40 healthy men found that a single intravenous infusion releases GH. | Placebo controlled sleep study, indexed in PubMed as a randomized controlled trial: four overnight 50 ug boluses raised GH, ACTH, cortisol, and stage 2 sleep. Oral dosing released GH in short children. A 2026 randomized phase III stroke trial gave GHRP-6 only with epidermal growth factor and missed its primary endpoint. |
| Evidence grade [1] [2] [6] [13] | Human RCT: one randomized, placebo controlled trial after bowel surgery found no benefit. No randomized trial for GH related uses. | Human RCT: randomized studies measured hormone and sleep responses, and a stroke trial tested it only in combination. No randomized trial for the uses it is sold for. |
| Appetite and metabolic effects [3] [8] [9] | Increased appetite reported anecdotally; ghrelin receptor activity also speeds gut motility, the basis of the ileus program. | Marked increase in hunger is its most consistent effect; FDA cited reduced insulin sensitivity and higher blood glucose. |
| Studied doses [2] [6] [7] | Human trial: 0.03 mg/kg intravenously twice daily for up to 7 days. No subcutaneous dose established. | Acute studies: 1 ug/kg or 4 x 50 ug intravenously; 300 ug/kg orally in children. No chronic dose established. |
| FDA compounding status [9] [10] [11] | 503A Category 2 in September 2023, 503A nominations withdrawn in 2024 and listed as a withdrawn 503A nomination in April 2026; ipamorelin acetate remains in 503B Category 2. | 503B Category 2 since September 2023, still listed as of April 2026; no 503A nomination or listing. |
| Note: Neither can be lawfully compounded; both are prohibited under WADA section S2. | ||
Evidence grade and regulatory status
Pulled from each peptide’s own record, so it stays in step with the peptide pages.
| Attribute | Ipamorelin | GHRP-6 |
|---|---|---|
| Class | Synthetic pentapeptide growth hormone secretagogue; selective agonist at the ghrelin receptor (GHS-R1a) | Synthetic hexapeptide growth hormone secretagogue (ghrelin receptor agonist), the first of the GHRP series |
| What it is | Growth hormone releaser acting on the hunger hormone (ghrelin) receptor; its one randomized placebo controlled trial, after bowel surgery, found no benefit. | Original growth hormone releasing peptide; randomized trials measured hormones, sleep, and a combination stroke therapy, not what it is sold for; WADA banned. |
| Evidence | Evidence: Human RCT evidence | Evidence: Human RCT evidence |
| FDA status | Regulatory: Nomination withdrawn | Regulatory: Not eligible for compounding |
| Compounding | Not FDA approved for any use. Ipamorelin was nominated for the 503A bulks list and placed in Category 2. FDA cited immunogenicity risk from aggregation or peptide related impurities, unnatural amino acids that complicate characterization, and a published report of serious adverse events, including a death, when it was given intravenously. On October 29, 2024 the Pharmacy Compounding Advisory Committee voted against adding ipamorelin free base or ipamorelin acetate to the 503A bulks list. FDA now lists ipamorelin acetate among 503A nominations withdrawn by the nominators, which puts it in no 503A category and outside FDA's interim policy. Ipamorelin acetate also remains in 503B Category 2, added September 29, 2023. It is not on the 503A bulks list, so as of the last verification date neither 503A pharmacies nor 503B outsourcing facilities have a federal basis to compound it. | Not FDA approved for any use. For 503A pharmacies, FDA lists GHRP-6 in Category 3, meaning it was nominated without enough support for FDA to evaluate it. It gets no protection under FDA's interim policy and is not on the 503A bulks list. For 503B outsourcing facilities, FDA placed GHRP-6 in Category 2 on September 29, 2023, citing immunogenicity risk from aggregation and impurities, effects on cortisol, and increased blood glucose from reduced insulin sensitivity. As of the last verification date no licensed pharmacy or outsourcing facility has a lawful basis to compound it. |
| WADA | WADA: WADA prohibited | WADA: WADA prohibited |
| Routes | Subcutaneous injection (as sold, no human pharmacokinetic publication), Intravenous infusion (human ileus trial), Intranasal (anti-doping metabolite study only) | Intravenous bolus (research studies), Oral (one pediatric study), Subcutaneous injection (as sold, not from published trials) |
| Typical cost | Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. | Not available through licensed US channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. |
| Last verified |
Has ipamorelin been tested directly against GHRP-6?
| Study | Design and population | Outcome | Grade |
|---|---|---|---|
| Ipamorelin, the first selective growth hormone secretagogue1998 PMID 9849822 | In vitro rat pituitary cell assays plus in vivo studies in anesthetized rats and conscious pigs, with GHRP-6 as comparatorRats and pigs (animal study) | Ipamorelin released GH with potency and efficacy comparable to GHRP-6 but, unlike GHRP-6, did not raise ACTH or cortisol | Evidence: Animal-only evidence |
What do ipamorelin and GHRP-6 cost?
| Dimension | Ipamorelin | GHRP-6 |
|---|---|---|
| Typical cost | Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. | Not available through licensed US channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. |
| Price detail | Ipamorelin price by channel | Price index in progress |
Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.
What's actually offered, what that means for you, and what to check if you're going ahead anyway: see the Ipamorelin page and the GHRP-6 page.
Frequently asked questions
Is ipamorelin better than GHRP-6?
It may be more selective: in the animal study that introduced it, ipamorelin released as much GH as GHRP-6 without raising ACTH or cortisol. But GHRP-6 has more human data, and no human trial has compared them, so there is no evidence ipamorelin is better in people. [1] [6]
Does GHRP-6 raise cortisol?
Yes. In a placebo controlled study in healthy men, overnight GHRP-6 boluses raised ACTH and cortisol along with GH. Reviews of the class also note prolactin increases. [6] [8]
Which one causes more hunger?
GHRP-6 is known for strong appetite stimulation. Ipamorelin also acts on the ghrelin receptor and increased appetite is reported anecdotally, but no human study has measured it. [1] [8]
Can I get either one from a licensed pharmacy?
No. GHRP-6 is in 503B Category 2 with no 503A pathway, and ipamorelin has only a withdrawn 503A nomination plus a 503B Category 2 listing for the acetate, so neither can be lawfully compounded. [9] [10]
Are they detectable in drug tests?
Yes. Both are prohibited under WADA section S2, and anti-doping methods detect urinary metabolites of GHRP-6 and ipamorelin after nasal dosing. [4] [11]
Conditions studied
From the blog
- Ipamorelin side effects and benefits: what studies show
Ipamorelin side effects in its one human trial matched placebo, but FDA flags serious events with IV use. Claimed benefits for muscle, fat loss, and sleep are untested. Not FDA approved.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998PubMed 9849822, 1998
- [2]Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014PubMed 25331030, 2014
- [3]Venkova K et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther 2009PubMed 19289567, 2009
- [4]Semenistaya E et al. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, hexarelin, and ipamorelin. Drug Test Anal 2015PubMed 25869809, 2015
- [5]Bowers CY et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984PubMed 6714155, 1984
- [6]Frieboes RM et al. Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology 1995PubMed 7617137, 1995
- [7]Bellone J et al. Growth hormone-releasing effect of oral GHRP-6 administration in children with short stature. Eur J Endocrinol 1995PubMed 7581965, 1995
- [8]Camanni F, Ghigo E, Arvat E. Growth hormone-releasing peptides and their analogs. Front Neuroendocrinol 1998PubMed 9465289, 1998
- [9]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list, content current as of April 22, 2026)FDA
- [10]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (503A bulks list, Category 1, 2, and 3 lists, and withdrawn nominations)FDA
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 30). Ipamorelin vs GHRP-6: evidence, cost, and legality. https://peptideagent.ai/compare/ipamorelin-vs-ghrp-6- HTML link
<a href="https://peptideagent.ai/compare/ipamorelin-vs-ghrp-6">Ipamorelin vs GHRP-6: evidence, cost, and legality</a>, PeptideAgent, updated September 30, 2026.